Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults - PubMed (original) (raw)
Review
Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults
Glenda MacQueen et al. Can J Psychiatry. 2017 Jan.
Abstract
Objective: This systematic review critically evaluated clinical practice guidelines (CPGs) for treating adults with major depressive disorder, dysthymia, or subthreshold or minor depression for recommendations following inadequate response to first-line treatment with selective serotonin reuptake inhibitors (SSRIs).
Method: Searches for CPGs (January 2004 to November 2014) in English included 7 bibliographic databases and grey literature sources using CPG and depression as the keywords. Two raters selected CPGs on depression with a national scope. Data extraction included definitions of adequate response and recommended treatment options. Two raters assessed quality using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument.
Results: From 46,908 citations, 3167 were screened at full text. From these 21 CPG were applicable to adults in primary care and outpatient settings. Five CPGs consider patients with dysthymia or subthreshold or minor depression. None provides recommendations for those who do not respond to first-line SSRI treatment. For adults with MDD, most CPGs do not define an "inadequate response" or provide specific suggestions regarding how to choose alternative medications when switching to an alternative antidepressant. There is variability between CPGs in recommending combination strategies. AGREE II ratings for stakeholder involvement in CPG development, editorial independence, and rigor of development are domains in which depression guidelines are often less robust.
Conclusions: About half of patients with depression require second-line treatment to achieve remission. Consistency and clarity in guidelines for second-line treatment of depression are therefore important for clinicians but lacking in most current guidelines. This may reflect a paucity of primary studies upon which to base conclusions.
Objectif:: Cette revue systématique a évalué de façon critique les guides de pratique clinique (GPC) sur le traitement des adultes souffrant de trouble dépressif majeur (TDM), de dysthymie, ou de dépression mineure ou infraliminaire pour des recommandations suivant une réponse inadéquate à un traitement de première ligne par inhibiteur spécifique du recaptage de la sérotonine (ISRS).
Méthode:: Les recherches dans les GPC (01/2004-11/2014) en anglais ont repéré 7 bases de données bibliographiques et des sources de littérature grise à l’aide des mots-clés GPC et dépression. Deux évaluateurs ont sélectionné un GPC sur la dépression ayant une portée nationale. Les extractions de données comprenaient des définitions de réponse adéquate et recommandaient des options de traitement. Deux évaluateurs ont estimé la qualité à l’aide de l’instrument Grille d’évaluation de la qualité des recommandations pour la pratique clinique (AGREE II).
Résultats:: Sur 46 908 citations, 3 167 ont été sélectionnées selon le texte intégral, 21 GPC uniques applicables aux adultes des soins de première ligne et des contextes ambulatoires ont été examinés. Cinq GPC abordent les patients souffrant de dysthymie ou de dépression mineure ou infraliminaire. Aucun n’offre de recommandations pour ceux qui ne répondent pas au traitement de première ligne par ISRS. Pour les adultes souffrant de TDM, la plupart des GPC ne définissent pas une « réponse inadéquate » et n’offrent pas de suggestions précises sur la façon de choisir des médicaments de rechange quand on passe à un autre antidépresseur. Il y a une variabilité entre les GPC qui recommandent des stratégies de combinaison. Les normes d’AGREE II pour la participation des intervenants à l’élaboration des GPC, l’indépendance éditoriale et la rigueur du développement sont des domaines dans lesquels les guides sur la dépression sont souvent moins fermes.
Conclusions:: Environ la moitié des patients souffrant de dépression nécessitent un traitement de deuxième ligne pour obtenir une rémission. La cohérence et la clarté des guides pour le traitement de deuxième ligne de la dépression sont donc importantes pour les cliniciens, mais elles sont absentes dans la plupart des guides actuels. Ceci peut refléter une rareté d’études primaires sur lesquelles fonder des conclusions.
Keywords: clinical practice guidelines; depression; inadequate response; systematic review.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
- Quality of clinical practice guidelines for inadequate response to first-line treatment for depression according to AGREE II checklist and comparison of recommendations: a systematic review.
Gabriel FC, Stein AT, de Melo DO, Henrique Fontes-Mota GC, Dos Santos IB, de Oliveira AF, Fráguas R, Ribeiro E. Gabriel FC, et al. BMJ Open. 2022 Apr 1;12(4):e051918. doi: 10.1136/bmjopen-2021-051918. BMJ Open. 2022. PMID: 35365512 Free PMC article. - Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
Edwards SJ, Hamilton V, Nherera L, Trevor N. Edwards SJ, et al. Health Technol Assess. 2013 Nov;17(54):1-190. doi: 10.3310/hta17540. Health Technol Assess. 2013. PMID: 24284258 Free PMC article. Review. - The Korean Medication Algorithm for Depressive Disorder: second revision.
Seok Seo J, Rim Song H, Bin Lee H, Park YM, Hong JW, Kim W, Wang HR, Lim ES, Jeong JH, Jon DI, Joon Min K, Sup Woo Y, Bahk WM. Seok Seo J, et al. J Affect Disord. 2014;167:312-21. doi: 10.1016/j.jad.2014.05.031. Epub 2014 May 29. J Affect Disord. 2014. PMID: 25010375 - Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK, Kruzikas DT, McLaughlin TP. Khandker RK, et al. J Manag Care Pharm. 2008 Jun;14(5):426-41. doi: 10.18553/jmcp.2008.14.5.426. J Manag Care Pharm. 2008. PMID: 18597572 Free PMC article. - Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
Ruhé HG, Huyser J, Swinkels JA, Schene AH. Ruhé HG, et al. J Clin Psychiatry. 2006 Dec;67(12):1836-55. doi: 10.4088/jcp.v67n1203. J Clin Psychiatry. 2006. PMID: 17194261 Review.
Cited by
- Association of Treatment With Antipsychotics, Antidepressants, or Both With Movement Disorders and Seizures Among Children and Adolescents With Depression in Korea.
Jeon SM, Park HY, Park S, Chung US, Kwon JW. Jeon SM, et al. JAMA Netw Open. 2022 Apr 1;5(4):e227074. doi: 10.1001/jamanetworkopen.2022.7074. JAMA Netw Open. 2022. PMID: 35426925 Free PMC article. - The Relationship of Early Sleep Improvement With Response to Pharmacotherapy in Unipolar Psychotic Depression.
Vos CF, Birkenhäger TK, Nolen WA, van den Broek WW, Ter Hark SE, Schellekens AFA, Verkes RJ, Janzing JGE. Vos CF, et al. J Clin Psychopharmacol. 2023 Nov-Dec 01;43(6):486-492. doi: 10.1097/JCP.0000000000001756. Epub 2023 Aug 31. J Clin Psychopharmacol. 2023. PMID: 37930199 Free PMC article. Clinical Trial. - Amantadine in Treatment of Dysthymia-The Pilot Case Series Study.
Krzystanek M, Martyniak E, Pałasz A, Skałacka K, Chwalba A, Wierzbiński P. Krzystanek M, et al. Pharmaceuticals (Basel). 2023 Jun 19;16(6):897. doi: 10.3390/ph16060897. Pharmaceuticals (Basel). 2023. PMID: 37375844 Free PMC article. - Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts.
Fabbri C, Hagenaars SP, John C, Williams AT, Shrine N, Moles L, Hanscombe KB, Serretti A, Shepherd DJ, Free RC, Wain LV, Tobin MD, Lewis CM. Fabbri C, et al. Mol Psychiatry. 2021 Jul;26(7):3363-3373. doi: 10.1038/s41380-021-01062-9. Epub 2021 Mar 22. Mol Psychiatry. 2021. PMID: 33753889 Free PMC article. - α7 Nicotinic acetylcholine receptor: a key receptor in the cholinergic anti-inflammatory pathway exerting an antidepressant effect.
Liu H, Zhang X, Shi P, Yuan J, Jia Q, Pi C, Chen T, Xiong L, Chen J, Tang J, Yue R, Liu Z, Shen H, Zuo Y, Wei Y, Zhao L. Liu H, et al. J Neuroinflammation. 2023 Mar 27;20(1):84. doi: 10.1186/s12974-023-02768-z. J Neuroinflammation. 2023. PMID: 36973813 Free PMC article. Review.
References
- Murray CJ, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740–743. - PubMed
- World Health Organization. The World Health Report 2001: mental health: new understanding, new hope. Geneva (Switzerland: ): WHO; 2001.
- The Standing Senate Committee on Social Affairs. Out of the shadows at last: transforming mental health, mental illness and addiction services in Canada. Ottawa: Parliment of Canada; 2006.
- Tompson MC, Pierre CB, Boger KD, et al. Maternal depression, maternal expressed emotion, and youth psychopathology. J Abnorm Child Psychol. 2010;38(1):105–117. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical